Bicycle Therapeutics/$BCYC
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Bicycle Therapeutics
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Ticker
$BCYC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
305
ISIN
US0887861088
Website
BCYC Metrics
BasicAdvanced
$515M
-
-$3.13
1.47
-
Price and volume
Market cap
$515M
Beta
1.47
52-week high
$27.11
52-week low
$6.10
Average daily volume
279K
Financial strength
Current ratio
14.857
Quick ratio
14.566
Long term debt to equity
0.352
Total debt to equity
1.124
Interest coverage (TTM)
-258.71%
Profitability
EBITDA (TTM)
-241.21
Gross margin (TTM)
-667.01%
Net profit margin (TTM)
-790.07%
Operating margin (TTM)
-965.55%
Effective tax rate (TTM)
2.64%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-21.69%
Return on equity (TTM)
-37.07%
Valuation
Price to revenue (TTM)
18.763
Price to book
0.7
Price to tangible book (TTM)
0.7
Price to free cash flow (TTM)
-2.651
Free cash flow yield (TTM)
-37.72%
Free cash flow per share (TTM)
-280.66%
Growth
Revenue change (TTM)
-38.18%
Earnings per share change (TTM)
-27.84%
3-year revenue growth (CAGR)
23.22%
3-year earnings per share growth (CAGR)
2.58%
What the Analysts think about BCYC
Analyst ratings (Buy, Hold, Sell) for Bicycle Therapeutics stock.
Bulls say / Bears say
Barclays has maintained a 'Buy' rating for Bicycle Therapeutics with a price target of $40.00, indicating confidence in the company's growth prospects. (Markets Insider)
Bicycle Therapeutics has secured approximately $555 million through PIPE financing, extending its financial runway into the second half of 2027, which supports ongoing research and development efforts. (Investing.com)
The company is expected to release more data updates in the second half of 2024, including information on Zelenectide Pevedotin in combination with pembrolizumab for first-line metastatic urothelial carcinoma treatment, as well as monotherapy in late-line triple-negative breast cancer and non-small cell lung cancer, which could positively impact stock performance. (Investing.com)
Bicycle Therapeutics' stock reached a 52-week low of $14.81, reflecting potential investor concerns about the company's short-term performance. (Investing.com)
B. Riley Securities downgraded Bicycle Therapeutics, anticipating muted stock movement from upcoming data readouts, suggesting potential challenges in meeting market expectations. (Seeking Alpha)
Leerink Partners issued a negative outlook for Bicycle Therapeutics' earnings, indicating concerns about the company's financial performance. (ETF Daily News)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
BCYC Financial Performance
Revenues and expenses
BCYC Earnings Performance
Company profitability
BCYC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bicycle Therapeutics stock?
Bicycle Therapeutics (BCYC) has a market cap of $515M as of July 04, 2025.
What is the P/E ratio for Bicycle Therapeutics stock?
The price to earnings (P/E) ratio for Bicycle Therapeutics (BCYC) stock is 0 as of July 04, 2025.
Does Bicycle Therapeutics stock pay dividends?
No, Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Bicycle Therapeutics dividend payment date?
Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicycle Therapeutics?
Bicycle Therapeutics (BCYC) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.